JCJason Choe

Jason Choe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jason Choe has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Impact of Statin Intensity on the Early Progression of Cardiac Allograft Vasculopathy

    by Xinyi Huang, Melana Yuzefpolskaya, Paolo C. Colombo, Jason Choe, Tara Shertel, Douglas L. Jennings

    Background: Limited research has compared the relative risks and benefits different statins have after heart transplantation (HT).Method: We hypothesize that higher statin intensity is associated with a smaller degree of allograft intimal thickening on intravascular ultrasound (IVUS) at 1‐year post‐HT. Allograft intima‐media thickness (IMT) on the first annual IVUS was retrospectively compared in patients initiated on a low‐intensity statin (pravastatin 20 mg daily) versus moderate‐intensity statin (atorvastatin 20 mg daily) post‐HT.Results: A total of 172 adult patients were included (2018–2022, n = 86 in each group). At 1 year, the maximal IMT was lower in the moderate‐intensity statin group, but the difference did not reach statistical significance. The LDL levels at 1 year trended lower with moderate‐intensity statin therapy, while the rates of adverse reactions were not statistically different. A multivariate analysis of the logistic regression model showed moderate statin intensity at 12 months was protective, while donor‐specific antibodies developed within the first‐year posttransplant were associated with IMT ≥ 0.5 mm on the first annual IVUS.Conclusion: This study found that using moderate‐intensity statin to prevent the early progression was as safe and possibly more effective than low‐intensity statin therapy for the prevention of early cardiac allograft vasculopathy.


  • Contemporary Immunosuppression Management and 1‐Year Outcomes in Dual Organ Heart Transplantation

    by Xinyi Huang, David Salerno, Danielle Kovac, Jenna Scheffert, Jessica Hedvat, Bayleigh Carver, Jason Choe, Tara Shertel, Melana Yuzefpolskaya, Paolo C. Colombo, et al.

    Background: There have been limited reports on immunosuppression strategies and outcomes in dual organ heart transplant populations, primarily from before the 2018 United Network for Organ Sharing (UNOS) heart allocation policy change. Recent data suggested that outcomes with heart–lung and heart–liver transplants remained comparable in the new allocation era, yet heart–kidney recipients have worse 1‐year survival.Methods: This single‐center retrospective study evaluated adult heart–kidney, heart–liver, and heart–lung transplant recipients from September 2019 to May 2023. Immunosuppression regimen, infectious complications, and graft outcomes were collected for 12 months.Results: A total of 36 patients (kidney n = 20, liver n = 9, and lung n = 7) were included in this study. Basiliximab was the most commonly employed induction strategy across the organ groups (12/20 in kidney, 4/9 in liver, and 7/7 in lung). All patients were on triple immunosuppression at 12 months posttransplant with prednisone wean achieved in one heart–liver recipient. Infection complications were frequently reported (95% kidney, 75% liver, 100% lung group). One patient went back to dialysis due to focal segmental glomerulosclerosis. One chronic lung allograft dysfunction was reported, but no other severe biopsy‐proven rejection or retransplant was reported. The 1‐year survival was 85% (17/20) in heart–kidney, 78% (7/9) in heart–liver, and 86% (6/7) in heart–lung recipients.Conclusion: This study summarized real‐world immunosuppression strategies and outcomes in dual organ heart transplant recipients.


  • Open Access

    The impact of statin intensity on long-term outcomes in elderly patients with acute myocardial infarction who have undergone percutaneous coronary intervention

    by J Choe, S H Lee, J H Ahn, J S Park, H W Lee, J H Oh, J H Choi, H C Lee, K S Cha, M H Jeong

    Background: The data regarding long-term clinical outcomes according to statin intensity in elderly patients who have undergone percutaneous coronary intervention (PCI) for acute myocardial infarction (MI) is unclear. Purpose: We aimed to investigate the long-term clinical benefit of high intensity statin versus moderate to low intensity statin in elderly patients underwent PCI for acute MI. Methods: Among 13104 patients with acute MI who have undergone PCI in a nationwide, prospective, and real-world registry, 4294 elderly (defined as ≥70 years) patients prescribed statin at discharge were included. 1136 patients were prescribed with high intensity statin, and 3158 patients were prescribed with moderate to low intensity statin. The major adverse cardiac events (MACE; all-cause death, recurrent MI, any revascularization, stroke, readmission due to heart failure [HF], or definite/probable stent thrombosis [ST]) and the components of MACE were compared in multivariable Cox regression, propensity score (PS) matched, and underwent PS-adjusted analyses. Results: During a median follow-up of 998 days, MACE, all-cause death, and cardiac death occurred in 1297 patients (30.2%), 737 patients (17.2%), and 460 patients (10.7%), respectively. The risks of MACE (entire: 26.9% vs. 31.4%, hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.73-0.95, p=0.005; PS-matched: n=2186, 25.3% vs. 30.8%, HR 0.79, 95% CI 0.67-0.94, p=0.008), all-cause death (entire: 14.4% vs. 18.1%, HR 0.78, 95% CI 0.65-0.93, p=0.005; PS-matched: 13.8% vs. 18.9%, HR 0.69, 95% CI 0.57-0.92, p=0.002), cardiac death (entire: 9.5% vs. 11.4%, HR 0.81, 95% CI 0.67-0.97, p=0.042; PS-matched: 8.7% vs. 11.3%, HR 0.77, 95% CI 0.61-0.96, p=0.031), and readmission due to HF (entire: 5.5% vs. 7.5%, HR 0.72, 95% CI 0.55-0.95, p=0.021; PS-matched: 5.7% vs. 8.1%, HR 0.78, 95% CI 0.59-0.96, p=0.017) were significantly decreased in the patients received high intensity statin compared to in those received moderate to low intensity statin. There were no significant differences in the risks of recurrent MI, any revascularization, stroke, and definite/probable ST between the groups. In patients ≥80 years, compared to the moderate to low intensity statin group, high intensity statin group had the reduced rates of MACE, all-cause death, cardiac death, recurrent MI, any revascularization, stroke, readmission due to HF, or definite/probable ST, but insignificantly. Conclusions: From the nationwide registry, we noted that in elderly patients after PCI for acute MI the administration of high intensity statin versus moderate to low intensity statin was contributed to the improved long-term clinical outcomes.

  • Open Access

    COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era

    by Jessica Hedvat, Nicholas W. Lange, David M. Salerno, Ersilia M. DeFilippis, Danielle Kovac, Heather Corbo, Justin K. Chen, Jason Y. Choe, Jennifer H. Lee, Anastasia Anamisis, et al.


  • Open Access

    New-Onset Diabetes in Patients Post-Heart Transplantation; the Role of Hypertension and Novel Diabetic Medications

    by H.S. Lumish, P.J. Kennel, D. Concha, A. Chung, D. Oren, S.S. Jain, D.L. Jennings, K.J. Clerkin, J.A. Fried, J. Raikhelkar, et al.


  • Nitazoxanide treatment for norovirus infection in solid organ transplant recipients

    by Jessica Hedvat, David M. Salerno, Danielle Kovac, Jenna L. Scheffert, Heather Corbo, Justin K. Chen, Jason Y. Choe, Douglas L. Jennings, Anastasia Anamisis, Esther C. Liu, et al.


  • Open Access

    Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants

    by Nicholas W. Lange, David M. Salerno, Douglas L. Jennings, Jason Choe, Jessica Hedvat, Danielle (Bley) Kovac, Jenna Scheffert, Tara Shertel, Lloyd E. Ratner, Robert S. Brown, et al.